
NanoViricides Advances Oral Ebola Treatment Candidate NV-387 Toward Phase II Trial in DRC
NanoViricides announces progress in developing NV-387, an oral gummies formulation for Bundibugyo ebolavirus, as the only oral Ebola treatment candidate under consideration for clinical trials amid a growing outbreak in the DRC.
Read full story

























